ENDRA Life Sciences Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.84 | $-0.63 | +25.0% | Beat |
| Q12026 FY2026 | $-1.23 | $-1.66 | -35.0% | Miss |
| Q42025 FY2025 | $-1.23 | $-1.67 | -35.8% | Miss |
Back to NDRA overview · NDRA holders · NDRA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.